Your session is about to expire
← Back to Search
BBP-398 for Cancer
Study Summary
This trial is testing a new drug to see if it is safe and works well against cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am over 18 and not pregnant.I have active brain metastases or carcinomatous meningitis.My cancer has MAPK-pathway changes and lacks standard treatment options.I am able to get out of my bed or chair and move around.I have another cancer that is getting worse or needs treatment.My organs are functioning well.My cancer has specific genetic features and I am joining the later phase of the trial.I am willing and able to follow the study's schedule and procedures.My cancer has MAPK-pathway changes and lacks standard treatment options.I have a serious heart condition.My tumor has a known activating mutation.I am able to care for myself and perform daily activities.I have a known tumor in my brain or spinal cord.I have been treated with a SHP2 inhibitor before.I can understand and am willing to sign the consent form for the study.My cancer has specific genetic features for the study.My organs are functioning well.I am over 18 years old and not pregnant.I cannot swallow pills or have a stomach condition that affects medication absorption.I am currently on dialysis.I have an active Hepatitis B, Hepatitis C, or HIV infection.I haven't had a stroke, heart attack, or severe chest pain in the last 6 months.I can understand and am willing to sign the consent form for the study.
- Group 1: Dose Expansion
- Group 2: Dose Escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How hazardous is BBP-398 (Formerly Known as IACS-15509) to human health?
"As this is a Phase 1 trial, our team at Power assigned BBP-398 (formerly IACS-15509) a score of 1 due to the limited data currently available on its safety and efficacy."
Can I still submit my information to be part of this experiment?
"Affirmative. According to the data available on clinicaltrials.gov, this medical research project was initiated on November 12th 2020 and is now actively recruiting participants. 130 individuals are needed across 6 different sites for enrolment in this trial."
What proportion of Canadian health facilities are currently undertaking this clinical experiment?
"6 distinct clinical trial sites are participating in this study. These include UCLA Hematology/Oncology - Santa Monica, The University of Texas MD Anderson Cancer Center and Huntsman Cancer Institute as well as 3 other medical centres."
What is the current sampling size of this clinical experiment?
"According to the study's criteria, 130 qualified candidates are needed for enrollment. Potential participants can find participating sites in Santa Monica, California and Houston, Utah; UCLA Hematology/Oncology - Santa Monica and The University of Texas MD Anderson Cancer Center respectively."
Share this study with friends
Copy Link
Messenger